このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

心臓ニューロモジュレーション療法のための新しいセットアップアルゴリズム (CS-10)

2026年10月2日 更新者:BackBeat Medical Inc

BackBeat Medical の Cardiac Neuromodulation Therapy (CNT) ペーシング信号用の新しいセットアップ アルゴリズムの臨床的実現可能性

After meeting all inclusion/exclusion criteria, subjects on standard pacing with the Moderato® or Moderato Plus Implantable Pulse Generator (IPG) will be subjected to two set-up sessions for the CNT algorithm: at week 4 and at week 6 post implant. At the end of these visits, subjects will undergo a 24 ambulatory blood pressure recording after which CNT will be automatically turned OFF and standard pacing will resume.

The ambulatory data will provide the basis for a lasting CNT programming by week 8. Follow up visits will be scheduled after 3, 6, and 12 months.

調査の概要

状態

募集

詳細な説明

This is a feasibility, pilot, interventional clinical study comparing the performance of CNT pacing signals delivered by Moderato® System or Moderato Plus using a new Setup Algorithm to the performance of the CNT pacing signals delivered by Moderato® System in a similar patient population in a previous multi-center, randomized, double blinded chronic trial (MODERATO II, described below).

Subjects meeting all eligibility criteria (detailed below) will receive a Moderato® IPG (Implantable Pulse Generator), either as a new implant or as a replacement to an existing pacemaker (visit 2). The subject will then be observed during the "Run-in Phase" for 30 days with the device programmed to deliver standard pacing therapy. During the "Run-In Phase", 3 weeks from implant (visit 3), the subjects will undergo a 24-hour Ambulatory Blood Pressure Measurement (ABPM). At the end of the "Run-in Phase" (4 weeks from implant at visit 4), eligibility for activation of CNT pacing signals will be re-established. Subjects eligibility will be determined following the result of the 24-hour ABPM conducted at week 3 from implant and office blood measurement at week 4 (inclusion criteria #5) and an assessment of change in ejection fraction from baseline using an echo measurement (exclusion criteria #5).

All subjects will undergo in visits 4 and 5 two sessions to test two different setup CNT Algorithms. One version will favor atrial pacing. The order of the setup versions will alternate, whereby subjects will start with setup version 1 or setup version 2 (see below). They will also undergo setup without the use of an algorithm, similar to the method used in the MODERATO II study.

After the "Run-In Phase", subjects meeting all eligibility criteria will undergo Setup Algorithm 1 (or 2). At the end of the visit, the Moderato® IPG will be programmed with the resulting CNT parameters to be delivered for 24 hours; after which the device will continue as a standard pacemaker with the pre-sets of the "Run-In Phase" period. Subjects will be fitted with 24 hour ABPM devices and sent home.

After two weeks (visit 5), subjects will return for the second setup visit. This time, subjects will undergo setup using the setup Algorithm version that was not used on them in the First Setup visit. They will also undergo setup without use of the algorithm, similar to the method used in the MODERATO II study. At the end of the second setup visit, the Moderato® IPG will be programmed using the resulting CNT parameters, to be delivered for 24 hours; after which the device will continue as a standard pacemaker with the pre-sets of the "Run-In Phase" period. Subjects will be fitted with 24 hour ABPM devices and sent home.

Subjects will return after two weeks for the trial CNT activation visit (visit 6). Based on the effect of the previous test CNT activations on blood pressure established by the two ABPM assessments, the investigator will decide whether to Continue CNT for the patient, with the parameters determined by the first or the second Setup Algorithm, or use the parameters established during setup without use of the algorithm.

Subjects will be further followed 3, 6 and 12 months post CNT activation (5, 8 and 14 months from implant) for changes in blood pressure and any adverse events (see study duration below).

At the end of the follow-up period, the treating physician will decide whether to leave CNT therapy on or off. Patient care will continue according to existing best practices.

研究の種類

介入

入学 (推定)

30

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

      • Prague、チェコ、15030
        • 募集
        • Nemocnice Na Homolce (Na Homolce Hospital)
        • コンタクト:
      • Budapest、ハンガリー、1122
        • 募集
        • Semmelweis University Heart and Vascular Center
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Béla Merkely, Prof.
      • Krakow、ポーランド、30-688
        • 引きこもった
        • Jagiellonian University Hospital
      • Poznan、ポーランド、61-848
        • まだ募集していません
        • Uniwersytecki Szpital Kliniczny w Poznaniu
        • コンタクト:
          • Przemysław Mitkowski, Dr.
      • Szczecin、ポーランド、72 70-111
        • まだ募集していません
        • Samodzielny Pub. Szpital Kliniczny nr 2 PUM
        • コンタクト:
          • Jaroslaw Kazmierczak, Prof. Dr.
      • Warsaw、ポーランド、02-097
        • まだ募集していません
        • Publiczny Centralny Szpital
        • コンタクト:
          • Marcin Grabowski, Prof. Dr.
      • Zabrze、ポーランド、41-800
        • 募集
        • Silesian Center for Heart Diseases
        • コンタクト:
          • Adam Sokal, Dr.

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Subject is ≥ 18 years of age
  • Subject requires implantation or replacement of a dual chamber pacemaker or requires an upgrade from a single chamber to a dual chamber pacemaker.
  • Subject has stable (for prior 1 month) hypertension treatment with 1, 2 or 3 antihypertensive drugs, which is planned to be maintained without changes for a period of at least 2 months post implant.
  • Subject has an office systolic blood pressure (oSBP) ≥140 and <180 mmHg
  • At 4 weeks from device implant, subject has an average 24-Hour ambulatory systolic blood pressure (aSBP) ≥130 mmHg and <170 mmHg and an office blood pressure (oSBP) ≥140 and <180 mmHg.
  • Subject is willing and able to comply with study visits and procedures
  • Subject is willing to adhere to the prescribed baseline antihypertension medical regimen for the duration of the study.

Exclusion Criteria:

  • 1. Subject has a known secondary cause of HTN (e.g. renal vascular disease, hyperthyroidism, hyperaldosterone and pheochromocytoma)
  • Subject has permanent atrial fibrillation
  • Subject has intermittent paroxysmal atrial fibrillation/flutter with significant burden (i.e., >10% atrial fibrillation/flutter beats if available.
  • Subject has an ejection fraction <50%
  • Subject has a drop of > 15% (absolute) in ejection fraction from baseline to week 4
  • Subject has symptoms of heart failure, NYHA Class II or greater
  • Subject has mitral regurgitation ≥2+, aortic stenosis with valve area <1.0 cm2 , or is expected to need a valve repair or replacement.
  • Subject has a history of stroke or TIA within 12 months or any prior stroke with a residual neurological deficit (modified Rankin Score >2+)
  • Subject experienced myocardial infarction (MI) within 3 months prior to enrolment
  • Subject had a cardiovascular interventional procedure or cardiovascular surgery within 6 months prior to enrolment
  • Subject has hypertrophic cardiomyopathy, restrictive cardiomyopathy or interventricular septal thickness ≥15 mm
  • Subject is on dialysis
  • Subject has estimated glomerular filtration rate (GFR) <30 ml/min/1.73m²
  • Subject has significant (>50% occlusion of left or right carotid artery) carotid artery stenosis
  • Subject has a history of clinically significant untreated ventricular tachyarrhythmia or has experienced sudden cardiac arrest
  • Subject has an active device-based treatment for hypertension
  • Subject has an existing active cardiac device or neurostimulator (e.g., ICD, spinal cord stimulator)
  • Subject has Type I Diabetes
  • Subject is a member of a vulnerable population (e.g., prisoners, pregnant or lactating women, mentally disabled)
  • Subject has the possibility of becoming pregnant during the conduct of the study and is not willing to use a means of contraception during the study
  • Subject cannot or is unwilling to provide informed consent

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:CNT Setup Algorithm Version 1

When performing the Setup Algorithm Version 1, each subject's blood pressure is measured with a standard cuff system while the BackBeat-CNT is activated, and system parameters are varied successively according to a specified sequence or based on the blood pressure measurements obtained during previous activations of BackBeat CNT, until the Setup Algorithm is complete. The parameter values as determined by the Setup Algorithm will constitute the programming of the Moderato IPG for the 24 hour activation following setup.

The effect of CNT on blood pressure will be obtained throughout the year long follow up period.

実験的:CNT Setup Algorithm Version 2

When performing the Setup Algorithm Version 1, each subject's blood pressure is measured with a standard cuff system while the BackBeat-CNT is activated, and system parameters are varied successively according to a specified sequence or based on the blood pressure measurements obtained during previous activations of BackBeat CNT, until the Setup Algorithm is complete. The parameter values as determined by the Setup Algorithm will constitute the programming of the Moderato IPG for the 24 hour activation following setup.

The effect of CNT on blood pressure will be obtained throughout the year long follow up period.

他の:CNT therapy optimization without use of the Setup Algorithm

For this optimization procedure, each subject's blood pressure is measured with a continuous blood pressure measurement system while the BackBeat-CNT is activated, and system parameters are varied according to a specified sequence until the desired blood pressure reduction is achieved. The parameter values that provide the desired blood pressure reduction will be recorded, for possible use by the investigator following trial completion

The effect of CNT on blood pressure will be obtained throughout the year long follow up period.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
CNT efficacy: Changes in average 24 hour systolic ambulatory blood pressure
時間枠:up to 12 Month follow-up visit

The change in the 24 hr blood pressure recording after each of the two set up sessions (week 4 and week 6) will be compared to the 24 hr ambulatory data of the control (week 3).

up to 12 Month follow-up visit
CNT safety: Incidence of device- and treatment-related adverse and serious adverse
時間枠:up to 12 Month follow-up visit

Incidence of device- and treatment-related adverse and serious adverse events during the study.

up to 12 Month follow-up visit

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Béla MERKELY, Prof. MD、Semmelweis University Heart and Vascular Center

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年6月21日

一次修了 (推定)

2027年1月31日

研究の完了 (推定)

2028年2月28日

試験登録日

最初に提出

2023年1月9日

QC基準を満たした最初の提出物

2023年2月6日

最初の投稿 (実際)

2023年2月9日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月6日

QC基準を満たした最後の更新が送信されました

2026年10月2日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する